>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Anti-Cetuximab Antibodies (Non-Neutralizing) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31, 10% human serum) and then add biotinylated cetuximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 39 ng/mL.
Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31) to the cetuximab.
Measured by its neutralizing ability in a functional ELISA. Immobilized cetuximab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Cetuximab Antibodies (Cat. No. CEB-Y31) and Biotinylated Human EGFRvIII (Cat. No. EGR-H82E0) with a inhibition rate of 0%.
Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y31) captured on CM5 chip via anti-mouse antibodies surface, can bind human cetuximab with an affinity constant of 0.421 nM.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.